PMD announces new ISIN code and timetable for reverse split of shares
Kurs
+63,67%
Prenumeration
Kalender
| Tid* | ||
| 2025-02-26 | N/A | Bokslutskommuniké 2024 |
| 2024-11-29 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-29 | - | Extra Bolagsstämma 2024 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-30 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
| 2024-05-29 | - | Årsstämma |
| 2024-05-28 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-29 | - | Bokslutskommuniké 2023 |
| 2024-01-31 | - | Split PMDS 128:1 |
| 2023-12-29 | - | Extra Bolagsstämma 2023 |
| 2023-11-28 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-30 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-27 | - | Årsstämma |
| 2023-05-24 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
| 2023-05-23 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-11-29 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-30 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-19 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
| 2022-05-17 | - | Årsstämma |
| 2022-05-17 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-11-23 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-24 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-28 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
| 2021-05-27 | - | Årsstämma |
| 2021-05-27 | - | Extra Bolagsstämma 2021 |
| 2021-05-27 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-23 | - | Bokslutskommuniké 2020 |
| 2020-11-24 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-25 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-27 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
| 2020-05-26 | - | Årsstämma |
| 2020-05-26 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-18 | - | Bokslutskommuniké 2019 |
| 2019-11-22 | - | Kvartalsrapport 2019-Q3 |
| 2019-10-22 | - | Extra Bolagsstämma 2019 |
| 2019-08-27 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-22 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
| 2019-05-21 | - | Årsstämma |
| 2019-05-21 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-26 | - | Bokslutskommuniké 2018 |
| 2018-11-23 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-20 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
| 2018-05-16 | - | Årsstämma |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-06 | - | Bokslutskommuniké 2017 |
| 2017-11-21 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-30 | - | Kvartalsrapport 2017-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
In connection with the reverse share split, whereby 128 shares are combined into one (1) new share, PMDS will receive a new ISIN code.
The last day of trading in PMD's share before the reverse share split is 30 January 2024 and the first day of trading in combined shares is 31 January 2024. PMD's share price will thus reflect the effect of the reverse share split as of 31 January 2024.
In connection with the reverse split, the PMD share (PMDS) will change its ISIN code as of 31 January 2024. The new ISIN code for PMD's share is SE0021513645.
Shareholders will automatically receive a new, lower number of shares in proportion to their holding on the record date of 1 February 2024. Shareholders whose holding of shares on the record date is not evenly divisible by 128 will receive shares free of charge in order to make the holding evenly divisible by 128. Provision of shares will be made through Euroclear Sweden AB, without any further action being required by shareholders.
Information about PMDS
PMD Device Solutions AB develops and sells medical products for respiratory monitoring in both the hospital and homecare setting. Its primary product is RespiraSense, a solution used for monitoring respiratory rate to support the detection of patient deterioration early and to avoid preventable respiratory failure and adverse patient outcomes. RespiraSense is, to the Company’s knowledge, the world’s only continuous, motion-tolerant respiratory rate monitor delivering class-leading reliability in measuring respiratory rate. RespiraSense is a novel technology that is commercialised in Europe, the UK, and FDA cleared in the US. The company’s shares are listed on Nasdaq First North Growth Market (STO: PMDS).
For additional information, please contact
Myles Murray, CEO
Phone: +353 86 887 4994
E-mail: myles@pmd-solutions.com & for general enquiries investor.relations@pmd-solutions.com
The Company’s Certified Adviser is Redeye.